Compugen Ltd (NASDAQ:CGEN) Reports Q2 2025 Revenue and EPS Miss, Shares Drop in Premarket

Compugen Ltd (NASDAQ:CGEN) Misses Revenue and EPS Estimates in Q2 2025, Shares Dip in Premarket

Compugen Ltd, a clinical-stage cancer immunotherapy company, reported its second-quarter 2025 financial results, falling short of analyst expectations on both revenue and earnings per share (EPS). The market reaction has been negative, with shares declining approximately 2% in premarket trading, extending a broader downtrend over the past month.

Key Financial Highlights vs. Estimates

• Reported Revenue: $1.26 million, significantly below the consensus estimate of $4.03 million.
• Reported EPS: -$0.08, worse than the estimated -$0.0663.
• Full-Year 2025 Estimates: Analysts project an EPS of -$0.2805 and sales of $15.07 million.
• Q3 2025 Estimates: Revenue is forecast at $4.18 million with an EPS of -$0.0663.

The substantial revenue miss suggests weaker-than-expected performance in monetizing its pipeline or collaborations. The wider-than-anticipated loss per share indicates higher operational costs or delays in clinical progress.

Market Reaction and Recent Performance

The immediate premarket decline reflects investor disappointment, particularly given the stock’s recent struggles:

• Last Week: -1.35%
• Last Two Weeks: -5.81%
• Last Month: -14.12%

The sustained downward trend suggests broader concerns beyond just the earnings miss, possibly linked to clinical trial timelines, funding needs, or competitive pressures in the immuno-oncology space.

Corporate and Clinical Updates

While the press release did not provide explicit forward-looking financial guidance, Compugen highlighted progress in its clinical programs, including:

• MAIA-Ovarian Platform Trial: The first patient was dosed in July 2025 in a study evaluating COM701 as maintenance therapy for platinum-sensitive ovarian cancer.
• Pipeline Focus: The company continues advancing its immuno-oncology candidates, emphasizing combinations with other therapies.

These developments are critical for long-term growth but may not immediately offset concerns over financial underperformance.

Looking Ahead

Investors will be watching for:

• Q3 Revenue Recovery: Whether the company can meet or exceed the $4.18 million estimate.
• Clinical Milestones: Updates on COM701 and other pipeline candidates that could drive partnerships or licensing deals.
• Cash Runway: Given the EPS miss, scrutiny may intensify on Compugen’s ability to fund operations without additional dilution.

For a deeper dive into Compugen’s earnings history and future estimates, see the full earnings and estimates breakdown.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.